Pluri Inc (PLUR) Stock Price, Quote & News

Company Profile

Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. Its product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatmen...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 74 710 8600

Website: www.pluri-biotech.com

Address:

MATAM Advanced Technology Park, Building No. 5, Haifa, Israel

focafoca99 Jun. 22 at 8:19 PM

$PLUR agrees to a $1.25 million advance subscription agreement to boost working capital, with the funds received June 16.

0 · Reply

PLURI_JUGGERNAUT_ Jun. 11 at 4:39 PM

$PLUR COFFEE AND CACAO BIOTECH SOLUTION TO CLIMATE CHANGE https://www.youtube.com/watch?v=Ql2snjmmZYs

0 · Reply

NVDAMillionaire Jun. 10 at 12:54 PM

$PLUR Great piece that accurately captures PLUR's current position. So if you want to refresh your understanding of PLUR or learn about PLUR for the first time, this is essential reading. https://everyticker.com/quote/PLUR/analysis/pluri-s-cellular-platform-faces-existential-liquidity-test-three-months-to-prove-diversification-strategy-nasdaq-plur

0 · Reply

PLURI_JUGGERNAUT_ Jun. 7 at 9:43 PM

$PLUR Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing https://markets.businessinsider.com/news/stocks/pluri-advances-toward-u-s-commercial-launch-through-its-subsidiary-cellav-following-completion-of-regenerative-aesthetic-products-listing-1036217213

0 · Reply

DJtraderNY May. 30 at 2:42 AM

$PLUR this thing still trading… knowing the trend id say better to short it always leading to another split

0 · Reply

PLURI_JUGGERNAUT_ May. 20 at 10:22 PM

$PLUR Chairman Alejandro Weinstein has invested a total of 11.5 million in Pluri Biotech through multiple strategic transactions across 2025 and 2026.

1 · Reply

Bumbleclod May. 20 at 9:14 PM

$PLUR scam stock sucking a salary off of shareholders for years......

0 · Reply

PLURI_JUGGERNAUT_ May. 20 at 1:21 PM

$PLUR Just Watched Yaky Yanay's AGP Presentation! (Laser Focused on Revenue Streams) !!! He Reminded Shareholders That Ever After Foods Alone, Currently Has A Valuation of 60 Million! Also, They Are Waiting For FDA/EMA/IMoH Approvals For CellaV Products Any Day Now !!!

0 · Reply

BioRich May. 20 at 7:02 AM

$TEM $URGN $PLUR $IVA $LGND (Sorry, using this is a placeholder to see how these track over time from today. Posting late so as to not clog the boards or appear as spam)

0 · Reply

hubal May. 18 at 10:56 AM

$PLUR Pluri Inc. (formerly Pluristem Therapeutics) reported its fiscal third-quarter 2026 earnings on May 14, 2026, posting an EPS of $-\$0.55$, beating the consensus estimate of $-\$0.66$ by $\$0.11$. Quarterly revenue reached $\$167,000$, which missed the estimated $\$660,000$.A more detailed breakdown of their latest financial performance includes:Net Loss: Totaled $\$5.55$ million for the quarter, reflecting a narrowing of the $-\$6.15$ million net loss from the same period in 2025.Fiscal Year-to-Date (Nine Months): The company recorded $\$681,000$ in total sales with a net loss of $-\$17.94$ million.Year-Over-Year Improvement: The quarterly loss per share improved significantly compared to the $-\$0.94$ basic and diluted EPS loss reported in Q3 of the previous year.

0 · Reply

Plurilock Announces Results of Annual General Meeting

Jun 2, 2026, 7:30 AM EDT - 27 days ago

Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing

2026-03-26T12:46:49.000Z - 3 months ago

Market Cap	21.92M
Revenue (ttm)	1.34M
Net Income (ttm)	-22.58M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,685.07%
Debt to Equity Ratio	-2.14

Volume	19,200
Avg Vol	12,616
Day's Range	N/A - N/A
Shares Out	10.79M
Stochastic %K	9%
Beta	0.64
Analysts	Strong Buy
Price Target	$12.00